硫酸新霉素市场－全球产业规模、份额、趋势、机会和预测，按销售管道、最终用途、地区和竞争细分，2020-2030 年

2024 年全球硫酸新霉素市值为 2.468 亿美元，预计到 2030 年将达到 3.8205 亿美元，复合年增长率为 5.22%。硫酸新霉素是一种广谱氨基糖苷类抗生素，广泛用于治疗人类和动物的细菌感染。它的有效性、可负担性以及在外用和口服製剂中的应用使其成为治疗皮肤病和胃肠道疾病等感染的首选。由于细菌感染发病率上升和对预防性医疗保健的日益重视，市场正在扩大，特别是在清洁水和卫生设施持续有限的发展中地区。硫酸新霉素的治疗多功能性及其成本效益继续支持其在製药和兽医领域的使用。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

不良副作用

主要市场趋势

兽医领域对硫酸新霉素的需求不断增长

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球硫酸新霉素市场的影响

第五章：全球硫​​酸新霉素市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按销售管道（直接、间接）
  • 依最终用途（皮肤感染、眼部感染、耳部感染、疫苗生产、兽医、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美硫酸新霉素市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲硫酸新霉素市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区硫酸新霉素市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美硫酸新霉素市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲硫酸新霉素市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：全球硫​​酸新霉素市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Neomycin Sulphate Market was valued at USD 246.80 million in 2024 and is projected to reach USD 382.05 million by 2030, growing at a CAGR of 5.22%. Neomycin sulphate, a broad-spectrum aminoglycoside antibiotic, is widely used to treat bacterial infections in both humans and animals. Its effectiveness, affordability, and application in topical and oral formulations make it a preferred choice in managing infections such as skin conditions and gastrointestinal disorders. The market is expanding due to rising incidences of bacterial infections and increased focus on preventive healthcare, especially in developing regions where limited access to clean water and sanitation persists. Neomycin sulphate's therapeutic versatility, combined with its cost-effectiveness, continues to support its use across both pharmaceutical and veterinary domains.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry is significantly driving demand for neomycin sulphate. With global healthcare generating over USD 4 trillion annually, the pharmaceutical and biotechnology segments alone account for approximately USD 850 billion. Neomycin sulphate plays a critical role in treating infections of the skin, eyes, and intestines, and is frequently used in both over-the-counter and prescription drugs. The growing burden of infectious diseases, especially in developing economies with inadequate sanitation infrastructure, reinforces the need for effective antimicrobials. Healthcare institutions rely heavily on neomycin sulphate for its broad-spectrum antibacterial capabilities, particularly in outpatient and surgical environments. As healthcare access improves globally, so does the reliance on reliable antibiotics like neomycin sulphate to manage and prevent infection-related complications.

Key Market Challenges

Adverse Side Effects

A major challenge in the global neomycin sulphate market is the potential for severe side effects associated with its prolonged or high-dose use. While effective, the antibiotic can cause nephrotoxicity and ototoxicity, leading to kidney damage and hearing loss. These risks have led to increased caution among healthcare providers and stricter regulatory oversight. As a result, neomycin sulphate usage is often limited to short-term or topical applications in human medicine. Meanwhile, the veterinary sector faces heightened scrutiny due to the risk of antibiotic residues in animal-derived products, which raises public health concerns. This has led to a gradual shift toward alternative antibiotics with better safety profiles.

Key Market Trends

Rising Demand of Neomycin Sulphate in Veterinary Sectors

A growing trend in the neomycin sulphate market is its increasing use in veterinary medicine. Chickens dominate global poultry production, comprising over 90% of the sector, followed by ducks, turkeys, guineafowl, and geese. As global demand for animal protein rises, so does the need for effective veterinary antibiotics. Neomycin sulphate is widely used to treat gastrointestinal and topical bacterial infections in livestock and poultry due to its proven efficacy against gram-negative bacteria. This trend is particularly pronounced in regions with large-scale animal farming operations, where maintaining animal health is essential for productivity and food safety.

Key Market Players

• Pfizer Limited
• Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• Myland Pharma Pvt Ltd
• Xi'an International Healthcare Factory Co., Ltd.
• Shandong Yifan Chemical Technology Co., Ltd.
• Xi'an Henrikang Biotech Co., Ltd.
• Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• Jinyao Xinrui Pharmaceutical
• Xinyu Pharmaceutical
• Renfu Pharmaceutical

Report Scope:

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neomycin Sulphate Market, By Sales Channel:

• Direct
• Indirect

Neomycin Sulphate Market, By End Use:

• Skin Infection
• Eye Infection
• Ear Infection
• Vaccine Production
• Veterinary Medicine
• Others

Neomycin Sulphate Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Neomycin Sulphate Market

5. Global Neomycin Sulphate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Neomycin Sulphate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neomycin Sulphate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Neomycin Sulphate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Neomycin Sulphate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Neomycin Sulphate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neomycin Sulphate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Neomycin Sulphate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Neomycin Sulphate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Neomycin Sulphate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Neomycin Sulphate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Neomycin Sulphate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neomycin Sulphate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Neomycin Sulphate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Neomycin Sulphate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Neomycin Sulphate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Neomycin Sulphate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Neomycin Sulphate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neomycin Sulphate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Neomycin Sulphate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Neomycin Sulphate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Neomycin Sulphate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neomycin Sulphate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Neomycin Sulphate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Neomycin Sulphate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neomycin Sulphate Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
• 15.3. Myland Pharma Pvt Ltd
• 15.4. Xi'an International Healthcare Factory Co., Ltd.
• 15.5. Shandong Yifan Chemical Technology Co., Ltd.
• 15.6. Xi'an Henrikang Biotech Co., Ltd.
• 15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
• 15.8. Jinyao Xinrui Pharmaceutical
• 15.9. Xinyu Pharmaceutical
• 15.10. Renfu Pharmaceutical

16. Strategic Recommendations

17. About Us & Disclaimer